Asklepios BioPharmaceutical, Inc. is a clinical-stage biotechnology company focused on developing therapies for patients with rare and orphan diseases. The company's lead product candidate, called LentiGlobin, is a gene therapy for the treatment of transfusion-dependent ?-thalassemia (TDT) and severe sickle cell disease (SCD). The company is also developing a pipeline of other gene therapies for rare diseases. Asklepios BioPharmaceutical was founded in 2003 and is headquartered in Lübeck, Germany.